Latest Breaking News On - சீன் கோலின்ஸ் - Page 2 : comparemela.com

Confirm TRV027 will be dosed in ~300 patients in nationwide trial led by Vanderbilt University Medical Center (VUMC) CHESTERBROOK, Pa., July 26, 2021 (GLOBE NEWSWIRE) Trevena, Inc. ( TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that the first COVID-19 patient has been enrolled in the NIH-funded ACTIV-4 Host Tissue (Accelerating COVID-19 Therapeutic Interventions and Vaccines) trial. “There is no one solution to end COVID-19, and we are honored to play a role in the global effort to overcome this pandemic and mitigate its long-term impact on our communities,” said Carrie Bourdow, President and CEO of Trevena. “I am excited that patients are now being enrolled in this study and that TRV027 is the one of the first active treatment arms available for patient randomization.”

United statesCarrie bourdowSasha bennettSean collinsFoundation for the national institutes of healthVanderbilt university medical centerTrevena incDepartment of defenseCompany annual report on formTrademark officeVanderbilt coordinating centerDepartment of healthBlood instituteNational heartClyde groupCenters for disease